Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
Morita, Akimichi, Takahashi, Hidetoshi, Ozawa, Kentaro, Imafuku, Shinichi, Nakama, Takekuni, Takahashi, Kenzo, Matsuyama, Takashi, Okubo, Yukari, Kitamura, Susumu, Matsuda, Naoto, Zhao, Yiwei, YokoyamJournal:
The Journal of Dermatology
DOI:
10.1111/1346-8138.14997
Date:
July, 2019
File:
PDF, 387 KB
2019